POS0283 TREATMENT PATTERNS AND CLINICAL CHARACTERISTICS OF PATIENTS WITH OSTEOARTHRITIS OF THE HIP AND/OR KNEE TREATED WITH TRADITIONAL NSAIDS VS COX-2S: A REAL-WORLD STUDY OF COMMERCIALLY-INSURED PATIENTS

Background: The 2019 American College of Rheumatology (ACR) guidelines strongly recommend oral nonsteroidal anti-inflammatory drugs (NSAIDs) for management hip and knee osteoarthritis (OA) topical NSAIDs OA. There are, however, important safety considerations with in terms increased rates gastrointestinal, cardiovascular, renal events. Given these risks, it is to understand the characteristics drug utilization patients who start treatment on different treatments (i.e., traditional [tNSAIDs] cyclooxygenase-2 inhibitors [COX-2s]). Objectives: goal this research was describe compare baseline commercially-insured diagnosed OA and/or started types tNSAIDs, COX-2s). Methods: Optum Healthcare Solutions, Inc. claims database (1/2012-3/2017) used identify ≥18 years old, ≥2 diagnoses OA, ≥90 days supply or COX-2s during one-year follow up period. index date defined as first prescription after diagnosis. Patients were assigned cohorts based type NSAID prescribed date. required be continuously-enrolled six months before (baseline period) 36 (follow-up Demographic clinical including age, sex, comorbidities, healthcare resource use (HRU) summarized baseline. Drug number prescriptions follow-up Results: Data 23,796 analyzed: 18,100 received 4,825 COX-2s, 871 tNSAIDs. initiated tNSAIDs youngest (mean age 60.6 vs. 64.6 65.0 tNSAIDs) had highest proportion female (71% 62% 63% cohort presence chronic kidney disease (2.6% 1.0% 1.5% respectively) congestive heart failure (2.5% 0.8% 1.7% at In HRU baseline, most emergency department visits (20.8% 16.7% both tNSAIDs), COX-2 inpatient (18.1% 15.4% 11.8% tNSAIDs). Oral lowest total all-cause cost ($6,504), costs ($8,455), but fairly comparable ($8,289). During follow-up, stayed mostly less than 15% later a 37% 56% took Topical an average 184.4 yet also extensively (average 315.5 383.5 days). Conclusion: This study suggests that more complex comorbidity profiles, higher adverse effects, often pharmacological However, switch other NSAIDs; frequently across cohorts. Thus, despite concerns are still placed manage their pain. need new innovative there currently lack options. Disclosure Interests: Stuart Silverman Consultant of: paid consultant Pfizer Eli Lilly Company connection study, Patricia Schepman Shareholder employee stock options, Employee Pfizer, James B Rice Brad Analysis Group, consultants Craig Beck Alan White Sheena Thakkar Michaela Johnson Rebecca Robinson minor stockholder Company, Birol Emir